What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer
MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.
Genentech’s Tecentriq decision puts Natera’s Signatera at the centre of precision bladder cancer care
Bladder cancer treatment is becoming more selective. Tecentriq’s ctDNA-guided approval may redefine who gets adjuvant immunotherapy.
Natera’s lung transplant biomarker study validates noninvasive dd-cfDNA surveillance model
Can a blood test replace lung biopsies? Natera’s Prospera test may reshape transplant care. Learn what the latest study means for diagnostics in organ health.
Why Illumina’s investment in MyOme could reset expectations for genome-based prevention
Illumina, Inc. and MyOme, Inc. have announced a new strategic collaboration, including an equity investment by Illumina to support MyOme’s upcoming Proactive Health (MPH) Trial. The large-scale clinical study, expected to begin in 2026, will evaluate the impact of artificial intelligence-integrated whole-genome sequencing on chronic disease prevention and cost savings across the U.S. healthcare system. […]